Literature DB >> 34550529

ImmunoPET: harnessing antibodies for imaging immune cells.

Anna M Wu1,2, Neeta Pandit-Taskar3,4,5.   

Abstract

Dramatic, but uneven, progress in the development of immunotherapies for cancer has created a need for better diagnostic technologies including innovative non-invasive imaging approaches. This review discusses challenges and opportunities for molecular imaging in immuno-oncology and focuses on the unique role that antibodies can fill. ImmunoPET has been implemented for detection of immune cell subsets, activation and inhibitory biomarkers, tracking adoptively transferred cellular therapeutics, and many additional applications in preclinical models. Parallel progress in radionuclide availability and infrastructure supporting biopharmaceutical manufacturing has accelerated clinical translation. ImmunoPET is poised to provide key information on prognosis, patient selection, and monitoring immune responses to therapy in cancer and beyond.
© 2021. World Molecular Imaging Society.

Entities:  

Keywords:  Antibodies; CD8; Cancer; ImmunoPET; Immunotherapy; T cells

Mesh:

Substances:

Year:  2021        PMID: 34550529     DOI: 10.1007/s11307-021-01652-7

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  96 in total

Review 1.  Single-cell RNA sequencing to explore immune cell heterogeneity.

Authors:  Efthymia Papalexi; Rahul Satija
Journal:  Nat Rev Immunol       Date:  2017-08-07       Impact factor: 53.106

Review 2.  Advances in PET Detection of the Antitumor T Cell Response.

Authors:  M N McCracken; R Tavaré; O N Witte; A M Wu
Journal:  Adv Immunol       Date:  2016-04-05       Impact factor: 3.543

Review 3.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

4.  Synthesis of 2'-deoxy-2'-[18F]fluoro-9-β-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET.

Authors:  Mohammad Namavari; Ya-Fang Chang; Brenda Kusler; Shahriar Yaghoubi; Beverly S Mitchell; Sanjiv Sam Gambhir
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 5.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 6.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

7.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

8.  [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity.

Authors:  Woosuk Kim; Thuc M Le; Liu Wei; Soumya Poddar; Jimmy Bazzy; Xuemeng Wang; Nhu T Uong; Evan R Abt; Joseph R Capri; Wayne R Austin; Juno S Van Valkenburgh; Dalton Steele; Raymond M Gipson; Roger Slavik; Anthony E Cabebe; Thotsophon Taechariyakul; Shahriar S Yaghoubi; Jason T Lee; Saman Sadeghi; Arnon Lavie; Kym F Faull; Owen N Witte; Timothy R Donahue; Michael E Phelps; Harvey R Herschman; Ken Herrmann; Johannes Czernin; Caius G Radu
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

Review 9.  Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

Authors:  Jérôme Galon; Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Anne Berger; Christine Lagorce; Alessandro Lugli; Inti Zlobec; Arndt Hartmann; Carlo Bifulco; Iris D Nagtegaal; Richard Palmqvist; Giuseppe V Masucci; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Michele Maio; Luigi Laghi; Fabio Grizzi; Martin Asslaber; Corrado D'Arrigo; Fernando Vidal-Vanaclocha; Eva Zavadova; Lotfi Chouchane; Pamela S Ohashi; Sara Hafezi-Bakhtiari; Bradly G Wouters; Michael Roehrl; Linh Nguyen; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Yili Wang; Scott Kopetz; Frank A Sinicrope; Viorel Scripcariu; Paolo A Ascierto; Francesco M Marincola; Bernard A Fox; Franck Pagès
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

Review 10.  Precision immunoprofiling by image analysis and artificial intelligence.

Authors:  Viktor H Koelzer; Korsuk Sirinukunwattana; Jens Rittscher; Kirsten D Mertz
Journal:  Virchows Arch       Date:  2018-11-23       Impact factor: 4.064

View more
  4 in total

Review 1.  Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications.

Authors:  Yi Li; Pei-Jun Liu; Zhuo-Li Zhang; Yi-Ning Wang
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

2.  Noninvasive Imaging of CD4+ T Cells in Humanized Mice.

Authors:  Veronica L Nagle; Charli Ann J Hertz; Kelly E Henry; Maya S Graham; Carl Campos; Nagavarakishore Pillarsetty; Andrea Schietinger; Ingo K Mellinghoff; Jason S Lewis
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

3.  Editorial to the Special Issue Entitled "Imaging in Immunooncology".

Authors:  Gilbert O Fruhwirth; Bettina Weigelin; Heike E Daldrup-Link; Vladimir Ponomarev
Journal:  Mol Imaging Biol       Date:  2022-04       Impact factor: 3.488

Review 4.  Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review.

Authors:  Elizabeth Katherine Anna Triumbari; David Morland; Riccardo Laudicella; Matteo Bauckneht; Domenico Albano; Salvatore Annunziata
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.